The global hematology drugs market reached a value of nearly $78,826.9 million in 2020, having increased at a compound annual growth rate (CAGR) of 6.3% since 2015. The market is expected to grow from $78,826.9 million in 2020 to $119,923.3 million in 2025 at a rate of 8.8%. The market is then expected to grow at a CAGR of 8.1% from 2025 and reach $176,969.5 million in 2030.
Growth in the historic period in the hematology drugs market resulted from rising cases of anemia globally, strong economic growth in emerging markets, rise in healthcare awareness and expenditure, increase in pharmaceutical R&D expenditure, and increase in insurance coverage. The market was restrained by pricing pressures from regulators, challenges due to regulatory changes, and low per capita healthcare expenditure.
Going forward, rising cases of anemia globally, growth in research and development, increasing geriatric population, and growing healthcare expenditure will drive the growth in the hematology drugs market. Factors that could hinder the growth of the market in the future include high costs of drugs and coronavirus pandemic.
The hematology drugs market is segmented by type into hemophilia, anemia, blood products and other blood disorder drugs. The hemophilia was the largest segment of the hematology drugs market segmented by type, accounting for 52.2% of the total in 2020. Going forward, the blood products segment is expected to be the fastest growing segment in the hematology drugs market segmented by type, at a CAGR of 10.8% during 2020-2025.
The hematology drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies/ drug stores and others. The hospital pharmacies was the largest segment of the hematology drugs market segmented by distribution channel, accounting for 52.5% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the hematology drugs market segmented by distribution channel, at a CAGR of 17.2% during 2020-2025.
The hematology drugs market is segmented by route of administration into oral and parenteral. The parenteral was the largest segment of the hematology drugs market segmented by route of administration, accounting for 76.2% of the total in 2020. Going forward, the oral segment is expected to be the fastest growing segment in the hematology drugs market segmented by route of administration, at a CAGR of 11.5% during 2020-2025.
Request Hematology Drugs Market PDF Sample: https://altusmarketresearch.com/hematology-drugs-global-market-43124
The hematology drugs market is segmented by drug classification into branded drugs and generic drugs. The branded drugs was the largest segment of the hematology drugs market segmented by drug classification, accounting for 89.4% of the total in 2020. Going forward, the generic drugs segment is expected to be the fastest growing segment in the hematology drugs market segmented by drug classification, at a CAGR of 12.9% during 2020-2025.
The hematology drugs market is segmented by mode of purchase into prescription drugs and over the counter drugs The prescription drugs was the largest segment of the hematology drugs market segmented by mode of purchase, accounting for 94.8% of the total in 2020. Going forward, the over-the-counter drugs segment is expected to be the fastest growing segment in the hematology drugs market segmented by mode of purchase, at a CAGR of 12.2% during 2020-2025.
Asia Pacific was the largest region in the hematology drugs market, accounting for 35.6% of the total in 2020. It was followed by the North America, Western Europe and then the other regions. Going forward, the fastest-growing regions in the hematology drugs market will be South America and Africa where growth will be at CAGRs of 12.0% and 11.5% respectively during 2020-2025. These will be followed by Middle East and Eastern Europe, where the markets are expected to register CAGRs of 11.2% and 8.5% respectively during 2020-2025.
The top ten competitors
The global hematology drugs market is fairly fragmented, with a small number of large players. The top ten competitors in the market made up to 17.96% of the total market in 2020. Major players in the market include Takeda Pharmaceutical Company, Roche Holding AG, Amgen Inc., Novartis AG, and Novo Nordisk A/S.
The op Opportunities in the Hematology Drugs Market
The top opportunities in the hematology drugs market segmented by type will arise in the hemophilia segment, which will gain $20,363.3 million of global annual sales by 2025.The top opportunities in the hematology drugs market segmented by distribution channel will arise in the retail pharmacies segment, which will gain $23,088.4 million of global annual sales by 2025. The top opportunities in the hematology drugs market segmented by route of administration will arise in the parenteral segment, which will gain $27,551.0 million of global annual sales by 2025. The top opportunities in the hematology drugs market segmented by drug classification will arise in the branded segment, which will gain $34,070.1 million of global annual sales by 2025. The top opportunities in the hematology drugs market segmented by mode of purchase will arise in the prescription segment, which will gain $37,945.2 million of global annual sales by 2025. The hematology drugs market size will gain the most in the China at $9,198.5 million.
